Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Compulsory License Costs Novartis 5 Percent In Thailand Sales

This article was originally published in PharmAsia News

Executive Summary

Switzerland's Novartis says Thailand's compulsory-licensing system for key drugs will hold its sales growth in the country to only 15 percent, below the 20 percent it had anticipated. The government overrode the Novartis patent earlier this year, allowing an India-made generic version of its cancer drug Femara (letrozole). Novartis avoided a similar CL on its other cancer drug, Gleevec (imatinib), by agreeing to provide some other drugs for free in Thailand. Novartis has a 4.4 percent sales share in Thailand, third behind Pfizer and Sanofi-Aventis. (Click here for more

You may also be interested in...



Abbott’s 3Q $8.9Bn Sales Beat Wall Street Consensus, Medtech Sales Up 3.4%

Abbott reported strong sales for diagnostics and devices in the third quarter and raised its full-year EPS guidance to $3.55 per share.

Vifor Confident About Prospects For Pruritus Dialysis Drug Korsuva

Vifor CEO Stefan Schulze tells Scrip that an expanded deal with Korsuva developer Cara Therapeutics means the US biotech will not have to invest in a commercial organization as the Swiss firm will mobilize its well-established sales force to launch the treatment for dialysis patients with CKD-associated pruritus.

Long-Term Data Confirm Durability Of Medtronic’s DTM Back Pain Therapy

A randomized trial demonstrated the superiority of Medtronic’s DTM spinal cord stimulation waveform over conventional spinal cord stimulation for treating back pain.

UsernamePublicRestriction

Register

GB150348

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel